Telescope Innovations Presents Results of First Fiscal Quarter 2024
Telescope Innovations Presents Results of First Fiscal Quarter 2024
The Company exceeded its quarterly revenue and profit records in Q1, 2024
該公司在2024年第一季度超過了其季度收入和利潤記錄
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended November 30, 2023. The Company generated revenues of $1.50 M for a net income of $215,000 (Figure 1).
不列顛哥倫比亞省溫哥華--（新聞檔案公司，2024年1月30日）——望遠鏡創新公司（CSE：TELI）（OTCQB：TELI）（OTCQB：TELIF）（”望遠鏡“或者”公司“）是全球製藥和化工行業先進技術和服務的開發商，報告了截至2023年11月30日的財季財務業績。該公司創造了150萬美元的收入，淨收入爲21.5萬美元（圖1）。
Figure 1. Revenue and net income chart for FY 2022, 2023, and 2024 to date.
圖 1。 迄今爲止的2022財年、2023年和2024財年的收入和淨收入圖表。
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED NOVEMBER 30, 2023
All values are represented in CAD.
截至2023年11月30日的財季財務摘要
所有值均在 CAD 中表示。
- Revenues of $1,504,852: representing 300% growth over Q1, 2023.
- Expenses of $1,289,852
- Net income of $215,000
- 收入爲1,504,852美元：比2023年第一季度增長300％。
- 支出爲1,289,852美元
- 淨收入爲215,000美元
"Our strong performance this quarter has been driven by the increasing momentum of our flagship product, DirectInject-LCTM," commented Jeffrey Sherman, COO of Telescope. "We have also continued to expand our technology and process development services with strategic partners in the pharmaceutical and chemical manufacturing sectors. Our automation and advanced analytical technology have been making big impacts in these industries by accelerating chemical process development, increasing data quality, and reducing development costs."
“我們本季度的強勁表現是由我們的旗艦產品勢頭增強所推動的， 直接注射液相色譜法TM，” 望遠鏡首席運營官傑弗裏·謝爾曼評論道。“我們還繼續與製藥和化學品製造領域的戰略合作伙伴一起擴大我們的技術和工藝開發服務。我們的自動化和先進的分析技術通過加速化學工藝開發、提高數據質量和降低開發成本，對這些行業產生了重大影響。”
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the quarter ended November 30, 2023, both of which are available under the profile for the Company on SEDAR+ ().
鼓勵讀者查看截至2023年11月30日的季度的完整財務報表以及隨附的管理層討論和分析，兩者均可在SEDAR+（）的公司簡介下查閱。
About Telescope
關於望遠鏡
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
Telescope是一家化學技術公司，爲製藥和化學行業開發可擴展的製造工藝和工具。該公司構建和部署新的支持技術，包括靈活的機器人平台和人工智能軟件，以提高實驗吞吐量、效率和數據質量。我們的目標是提供現代化學技術解決方案，以應對健康和可持續發展方面最嚴峻的挑戰。
On behalf of the Board,
代表董事會，
Telescope Innovations Corp.
望遠鏡創新公司
Jeffrey Sherman, Chief Operating Officer
E: jeff@telescopeinn.com
傑弗裏·謝爾曼，首席運營官
E: jeff@telescopeinn.com
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE既未批准也未拒絕本新聞稿的內容。CSE及其市場監管機構（該術語在CSE的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問